The Igloo-CF Study

  • Research type

    Research Study

  • Full title

    The Impact of Gut dysbiosis on Lung inflammation : an ObservatiOnal study in cystic fibrosis (The Igloo Study)

  • IRAS ID

    246456

  • Contact name

    Daniel Peckham

  • Contact email

    d.g.peckham@leeds.ac.uk

  • Sponsor organisation

    University of Leeds

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Cystic fibrosis (CF) is a condition which markedly impacts the lungs and gut. Lung inflammation, recurrent chest infections and declining lung function are cardinal features of CF. Therefore, focusing research on factors contributing to inflammation is imperative. A potential candidate may be the gut microbiome. While it is known the gut microbiome can impact gut inflammation and interact with the immune system, there is increasing evidence it could also alter inflammatory and immune responses in the lungs. Potentially substances, such as short chain fatty acids, produced by the microbiota are having a long-range influence on lung biology. Due to the condition itself, its treatments (including recurrent antibiotics) and altered diet in individuals with CF their gut microbiota may be altered. Therefore, understanding the interaction between the CF host and gut microbiota and the influence of dietary intervention on local, systemic and lung inflammation will provide new insights into how the gut microbiota contributes to disease progression and whether dietary modification could be exploited to alter CF pulmonary disease. This is a prospective observational study investigating the correlation between gut microbiome, abdominal symptoms, antibiotics and medications, diet, blood metabolites (metabolomics) and accelerated decline in lung function in patients with CF. It is to be conducted across three adult regional CF centres. Data will be collected from participants 18 years or above with CF at two time points six months apart. Data collected includes: stool samples, blood samples, dietary intake, abdominal symptoms and antibiotics taken.

  • REC name

    London - Bromley Research Ethics Committee

  • REC reference

    18/LO/2241

  • Date of REC Opinion

    31 Jan 2019

  • REC opinion

    Further Information Favourable Opinion